Product Information
VIREAD 300 MG TABLET is a brand product labeled by Gilead Sciences, Inc., priced at $40.6865 per EA under NDC 61958040101. Its NADAC has been published 593 times since Nov 28, 2013.
FDA first approved this application on Oct 26, 2001. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the TENOFOVIR DISOPROXIL FUMARATE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
300 mg/1
Manufacturer
Gilead Sciences, Inc.NDC
61958040101
Classification
Brand
Dosage Form
TABLET, COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TENOFOVIR DISOPROXIL FUMARATEApproval Type
New Drug (NDA)
FDA Application
NDA021356FDA Approved
10/26/2001
TE Code
AB
On Market Since
10/26/2001
Pharmacological Classes
Price Statistics
The NADAC for VIREAD 300 MG TABLET has been published 593 times since Nov 28, 2013, and over the history we have for it it has risen 49.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $40.6865 per EA |
|---|---|
| All-time high | $40.8083 (Jun 12, 2024) |
| All-time low | $26.7325 (Dec 18, 2013) |
| 52-week high | $40.7318 |
| 52-week low | $40.6615 |
| Median price | $38.7035 |
| Average price | $36.5285 |
| Largest weekly change | +6.9% (Jan 14, 2015) |
| Weeks tracked | 593 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the TENOFOVIR DISOPROXIL FUMARATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Gilead Sciences, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
TENOFOVIR DISOPROXIL FUMARATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VIREAD 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for VIREAD 300 MG TABLET, manufactured by Gilead Sciences, Inc., is $40.6865 per EA (NDC 61958040101), effective Sep 30, 2026.
How has the price of VIREAD 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for VIREAD 300 MG TABLET has risen 49.9%. It has been tracked across 593 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for VIREAD 300 MG TABLET?
Since Nov 28, 2013, the NADAC for VIREAD 300 MG TABLET has ranged from a low of $26.7325 (Dec 18, 2013) to a high of $40.8083 (Jun 12, 2024), with a median of $38.7035 per EA.
Are there cheaper alternatives to VIREAD 300 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of VIREAD 300 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures VIREAD 300 MG TABLET?
VIREAD 300 MG TABLET (NDC 61958040101) is labeled by Gilead Sciences, Inc., and CMS classifies it as a brand product.